Search

Home > Epilepsy Talk Radio > SAGE Trial for Refractory Status Epilepticus
Podcast: Epilepsy Talk Radio
Episode:

SAGE Trial for Refractory Status Epilepticus
Category: Health
Duration: 00:21:00
Publish Date: 2014-06-11 14:00:00
Description: In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com, interviews Steve Kanes, MD, PhD, Chief Medical Officer at SAGE Therapeutics about the SAGE 547 Trial in Status Epilepticus. SAGE-547 is currently being evaluated in a Phase 1/2 clinical trial for super-refractory status epilepticus (SRSE). SAGE-547 demonstrated robust findings in preclinical models of SE, including significantly increased efficacy over current standard-of-care benzodiazepine treatment, and compelling early human experience data. After the interview, you can learn more about refractory epilepsy at: http://www.epilepsy.com/learn/refractory-epilepsy.
Total Play: 0